Mxra8-Targeted Fusion Proteins for Alphavirus Entry Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies are inadequate in effectively inhibiting arthritogenic alphavirus infections, which are caused by viruses such as Chikungunya, Mayaro, Ross River, and Semliki Forest viruses, due to the lack of targeted interventions against the Mxra8 receptor, leading to uncontrolled viral entry and inflammation.
Innovation Solution
Development of fusion proteins comprising an Fc region and Mxra8 regions or functional variants, administration of Mxra8 inhibiting agents like anti-Mxra8 antibodies or small molecule inhibitors, and genetic modification using CRISPR-Cas9 to reduce or prevent Mxra8 expression, thereby blocking viral entry and reducing inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Mxra8 receptor is present on host cells, then alphavirus can enter and infect cells, but this leads to uncontrolled viral infection and inflammation
Solution Approach 1:
The patent uses Mxra8 inhibiting agents as intermediary substances that bind to the Mxra8 receptor, preventing viral attachment while maintaining normal cellular functions. These agents act as mediators between the virus and host cell, blocking the harmful interaction without eliminating the receptor's physiological roles.
Solution Approach 2:
The invention applies preliminary anti-action by administering Mxra8 inhibiting agents before or during viral infection to prevent virus-receptor binding. This preemptive blocking prevents the chain of infection events from initiating, thereby controlling viral entry and preventing subsequent inflammation.
2Reliability
If fusion proteins with Mxra8 regions are developed, then targeted inhibition of viral entry is achieved, but device complexity increases
Solution Approach 1:
The patent merges the Mxra8 receptor-binding domain with the Fc region of antibodies to create fusion proteins. This combination allows the protein to both bind to the viral receptor (inhibiting entry) and engage immune system components (enhancing clearance), achieving multiple functions in a single molecular structure.
Solution Approach 2:
The fusion proteins exhibit multi-functionality by simultaneously serving as receptor blockers, antibody effector engagement molecules, and potential immunomodulators. This universal design allows a single agent to address multiple aspects of viral infection and host response.
3Reliability
If genetic modification to reduce Mxra8 expression is implemented, then viral infection is prevented, but manufacturing precision and genetic editing accuracy are required
Solution Approach 1:
CRISPR-Cas9 and similar gene editing systems serve as intermediary tools that precisely modify the Mxra8 gene without completely eliminating it. This allows controlled reduction of receptor expression levels, preventing viral infection while maintaining enough receptor function for normal cellular processes.
Solution Approach 2:
The invention changes the expression parameter of Mxra8 from normal levels to reduced levels through genetic modification. This parameter change is sufficient to block viral entry while preserving essential physiological functions that depend on Mxra8, achieving infection prevention without complete receptor abolition.
Data Source
AI summary
Among the various aspects of the present disclosure is the provision of compositions and methods of treating arthritogenic alphavirus infection and methods of screening.